Korean Journal of Schizophrenia Research (대한조현병학회지)

Korean Society for Schizophrenia Research (대한조현병학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment-Resistant Schizophrenia: Terminology and Clinical Features

치료저항성 조현병: 정의와 임상양상

  • Lee, Kounseok (Department of Psychiatry, Hanyang University Medical Center)
  • 이건석 (한양대학교병원 정신건강의학과)
  • Received : 2020.09.28
  • Accepted : 2020.10.11
  • Published : 2020.10.30
⟨ Previous Next ⟩

Abstract

Schizophrenia is one of serious mental illnesses and is often described as a heterogeneous disorder. Approximately one-third of schizophrenia cases are treatment-resistant schizophrenia (TRS). The aim of this study was to review the definitions and clinical features of TRS. Though it was found that the criteria for TRS were considerably diverse, the Treatment Response and Resistance in Psychosis (TRRIP) consensus criteria were recently introduced. According to the TRRIP criteria, TRS should be suspected if symptoms persist alongside psychotic symptoms despite sufficient treatment for ≥12 weeks, or two or more symptoms persist significantly for ≥6 weeks. The clinical characteristics of TRS includes an earlier age of onset, more severe and familial form, possibly more rural residence, unlikely association with male sex, and an increase in cognitive deficits.

Keywords

References

  1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005;2:e141. https://doi.org/10.1371/journal.pmed.0020141
  2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796. https://doi.org/10.1001/archpsyc.1988.01800330013001
  3. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544. https://doi.org/10.1001/archpsyc.1992.01820070032005
  4. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993;19:287-302. https://doi.org/10.1093/schbul/19.2.287
  5. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993;29:309-314.
  6. Barnes TR, McEvedy CJ. Pharmacological treatment strategies in the non-responsive schizophrenic patient. Int Clin Psychopharmacol 1996;11 Suppl 2:67-71. https://doi.org/10.1097/00004850-199605002-00011
  7. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of partients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56. https://doi.org/10.1176/appi.ajp.161.1.1
  8. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz W, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13:318-378. https://doi.org/10.3109/15622975.2012.696143
  9. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. London: National Institute for Health and Care Excellence;2014.
  10. Lee JS, Yun JY, Kang SH, Lee SJ, Choi JH, Nam B, et al. Korean Medication Algorithm for Schizophrenia 2019, second revision: treatment of psychotic symptoms. Clin Psychopharmacol Neurosci 2020;18:386-394. https://doi.org/10.9758/cpn.2020.18.3.386
  11. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017;174:216-229. https://doi.org/10.1176/appi.ajp.2016.16050503
  12. Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am 2007;30:511-533. https://doi.org/10.1016/j.psc.2007.04.001
  13. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996;32:683-697.
  14. Lieberman JA. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J Clin Psychiatry 1999;60 Suppl 12:9-12. https://doi.org/10.4088/JCP.v60n0104
  15. Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q 2000;71:373-384. https://doi.org/10.1023/A:1004640408501
  16. Thorup A, Waltoft BL, Pedersen CB, Mortensen PB, Nordentoft M. Young males have a higher risk of developing schizophrenia: a Danish register study. Psychol Med 2007;37:479-484. https://doi.org/10.1017/S0033291707009944
  17. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 1997;154:475-482. https://doi.org/10.1176/ajp.154.4.475
  18. Teo C, Borlido C, Kennedy JL, De Luca V. The role of ethnicity in treatment refractory schizophrenia. Compr Psychiatry 2013;54:167-172. https://doi.org/10.1016/j.comppsych.2012.07.002
  19. Wimberley T, Stovring H, Sorensen HJ, Horsdal HT, MacCabe JH, Gasse C. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry 2016;3:358-366. https://doi.org/10.1016/s2215-0366(15)00575-1
  20. Povlsen UJ, Norrng U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71:176-185. https://doi.org/10.1111/j.1600-0447.1985.tb01268.x
  21. Kuha S, Miettinen E. Long-term effect of clozapine in schizophrenia a retrospective study of 108 chronic schizophrenics treated with clozapine for up to 7 years. Nord Psykiatr Tidsskr 1986;40:225-230. https://doi.org/10.3109/08039488609096470
  22. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99 Suppl:S18-S27. https://doi.org/10.1007/BF00442554
  23. Vassos E, Pedersen CB, Murray RM, Collier DA, Lewis CM. Meta-analysis of the association of urbanicity with schizophrenia. Schizophr Bull 2012;38:1118-1123. https://doi.org/10.1093/schbul/sbs096
  24. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013;45:1150-1159. https://doi.org/10.1038/ng.2742
  25. Joober R, Rouleau GA, Lal S, Bloom D, Lalonde P, Labelle A, et al. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients. Schizophr Res 2005;77:35-41. https://doi.org/10.1016/j.schres.2005.01.008
  26. Kinon BJ. The Group of Treatment Resistant Schizophrenias. Heterogeneity in treatment resistant schizophrenia (TRS). Front Psychiatry 2018;9:757. https://doi.org/10.3389/fpsyt.2018.00757
  27. Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E, et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuropsychopharmacol Biol Psychiatry 2016;65:34-48. https://doi.org/10.1016/j.pnpbp.2015.08.010
  28. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 2014;29:63-76. https://doi.org/10.1097/YIC.0b013e32836508e6
  29. Schennach R, Riedel M, Musil R, Moller HJ. Treatment Response in First-episode Schizophrenia. Clin Psychopharmacol Neurosci 2012;10:78-87. https://doi.org/10.9758/cpn.2012.10.2.78
  30. Hollis C. Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity. Am J Psychiatry 2000;157:1652-1659. https://doi.org/10.1176/appi.ajp.157.10.1652
  31. Reichert A, Kreiker S, Mehler-Wex C, Warnke A. The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child Adolesc Psychiatry Ment Health 2008;2:6. https://doi.org/10.1186/1753-2000-2-6
  32. Kayo M, Tassell I, Hiroce V, Menezes A, Elkis H. Does lack of improvement in the first two weeks predict treatment resistance in recent-onset psychosis? Clinics 2012;67:1479-1482. https://doi.org/10.6061/clinics/2012(12)20
  33. Joober R, Rouleau GA, Lal S, Dixon M, O'Driscoll G, Palmour R, et al. Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers. Schizophr Res 2002;53:229-238. https://doi.org/10.1016/S0920-9964(01)00279-1
  34. de Bartolomeis A, Balletta R, Giordano S, Buonaguro EF, Latte G, Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res 2013;210:387-395. https://doi.org/10.1016/j.psychres.2013.06.042
  35. Frydecka D, Beszlej JA, Goscimski P, Kiejna A, Misiak B. Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Res 2016;235:133-138. https://doi.org/10.1016/j.psychres.2015.11.028
  36. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999;60 Suppl 12:22-23. https://doi.org/10.4088/JCP.v60n0105
  37. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007;18:39-60. https://doi.org/10.1177/0957154X07070335
  38. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-526. https://doi.org/10.1176/appi.ajp.158.4.518
  39. Ucok A, Cikrikcili U, Karabulut S, Salaj A, Ozturk M, Tabak O, et al. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. Int Clin Psychopharmacol 2015;30:290-295. https://doi.org/10.1097/YIC.0000000000000086
  40. Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Olie JP, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol 2006;29:28-33. https://doi.org/10.1097/00002826-200601000-00009
  41. Samanaite R, Gillespie A, Sendt KV, McQueen G, MacCabe JH, Egerton A. Biological predictors of clozapine response: a systematic review. Front Psychiatry 2018;9:327. https://doi.org/10.3389/fpsyt.2018.00327
  42. Okhuijsen-Pfeifer C, Sterk A, Horn I, Terstappen J, Kahn R, Luykx J. Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis. Neurosci Biobehav Rev 2020;111:246-252. https://doi.org/10.1016/j.neubiorev.2020.01.017
  43. Maccall C, Billcliff N, Igbrude W, Natynczuk S, Spencer E, Flanagan R. Clozapine: more than 900 mg/day may be needed. J Psychopharmacol 2009;23:206-210. https://doi.org/10.1177/0269881108089819